Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

ECI COPD Course Lercture 2


Published on

ECI COPD Educator course.

Published in: Health & Medicine
  • Be the first to comment

ECI COPD Course Lercture 2

  1. 1. Pharmacology for COPD
  2. 2. GOLD Goals for COPD treatmentDisease Management should now be focusing on 2 key areas1. Reducing Symptoms2. Reducing Risk. Adapted from GOLD 2013
  3. 3. GOLD 2013 Combined assessment of COPD GOLD 4 ≥2 GOLD 3 Less symptoms More symptomsSPIROMETRIC CLASSIFICATION EXACERBATION /YEAR High risk high risk GOLD 2 <2 Less symptoms More symptoms GOLD 1 Low risk low risk mMRC 01 mMRC ≥2 CAT <10 SYMPTOMS CAT ≥10 Adapted from GOLD 2013
  4. 4. Pharmacological Treatment Patient Recommended Alternative Choice Other possible treatments First Choice LAMA SAMA prn or A or LABA Theophylline SABA prn or SABA and SAMA LAMA SABA and/or SAMA B or LAMA and LABA Theophylline LABA ICS + LABA LAMA and LABA SABA and/or SAMA C or LAMA + PDE4-inh. Theophylline LAMA LABA + PDE4-inh. ICS + LABA ICS + LABA and LAMA or Carbocysteine And/ or ICS+LABA and PDE4-inh. or D SABA and/or SAMA LAMA LAMA and LABA or Theophylline LAMA and PDE4-inh.(Medications in each box are mentioned in alphabetical order, and therefore not necessarily in order of preference.)*Alternative medications can be used alone or in combination with other options in the First and Second columns Adapted from GOLD 2013
  5. 5. Patient Type (A) Treatment Options 1st Recommended choice : <2 • SABA Prn Or SAMA Prn GOLD 2 EXACERBATION /YEAR Alternative Choice: • LABA Or LAMA Or GOLD 1 Less symptoms •SABA and SAMA Low risk Other Possible treatments *: mMRC 01 • Theophylline CAT <10* Medications can be used alone or in combination with other options in the First recommended or alternative choices Adapted from GOLD 2013
  6. 6. Short acting bronchodilatorsUsed as reliever medicationTypes: ▫ Β2 agonists  Salbutamol ▫ Anlicholinergics:  Ipratroium
  7. 7. Potential Side Effects of COPDtherapy: β2 AgonistsSide effects include: ▫ Resting sinus tachycardia ▫ Ventricular arrhythmias (rare) ▫ Somatic tremor ▫ Hypokalemia ▫ Mild falls in PaO2
  8. 8. Potential Side Effects of COPDTherapy: Anticholinergic AgentsSide effects are less common versus systemic agents (e.g., atropine) ▫ Dry mouth is most commonly reported adverse event (related to local deposition of agent) ▫ Possible worsening of glaucoma ▫ Occasional prostatic symptoms
  9. 9. Patient Type (B) Treatment Options 1st Recommended choice : <2 LABA or LAMA EXACERBATION /YEAR GOLD 2 Alternative Choice: • LABA and LAMA GOLD 1 More symptoms Other Possible treatments *: low risk • SABA and/or SAMA • Theophylline mMRC ≥2 CAT ≥10* Medications can be used alone or in combination with other options in the First recommended or alternative choices Adapted from GOLD 2013
  10. 10. Long-acting Bronchodilators inCOPDPatients with dyspnea that is not relieved by the as-needed use of a short-acting bronchodilator should have a long acting Inhaled bronchodilator added to therapyThese agents include: ▫ Formoterol ▫ Indacaterol ▫ Tiotropium ▫ Salmeterol
  11. 11. LABAs in COPD guidelines British Thoracic Society suggest that long-acting bronchodilator therapy should always be considered when patients with COPD are symptomatic GOLD treatment recommendations for patients with stable COPD are characterized by a stepwise increase in therapy according to disease severity ATS/ERS COPD guidelines have indicated the importance of starting regular maintenance therapy based on the presence of persistent symptoms, regardless of the disease stage. The choice of agents may be based primarily on individual response, cost, side-effect profile and availability. International Journal of COPD 2008:3(4) 521–529
  12. 12. Patient Type (C) Treatment Options 1st Recommended choice : LABA + ICS ≥2 Or EXACERBATION /YEAR •LAMA GOLD 4 Alternative Choice: •LABA and LAMA Less symptoms GOLD 3 •LAMA + PDE4-inh. High risk •LABA + PDE4-inh. mMRC 01 Other Possible treatments *: CAT <10 •SABA and/or SAMA •Theophylline* Medications can be used alone or in combination with other options in the First recommended or alternative choices Adapted from GOLD 2013
  13. 13. Patient Type (D) Treatment Options 1st Recommended choice : • LABA + ICS And / or LAMA ≥2 EXACERBATION /YEAR Alternative Choice: GOLD 4 • LABA + ICS and LAMA or • LABA + ICS and PDE4-inh. or • LABA and LAMA or More symptoms GOLD 3 high risk • LAMA and PDE4-inh. Or Other Possible treatments *: • Carbocysteine mMRC ≥2 • SABA and/or SAMA CAT ≥10 • Theophylline* Medications can be used alone or in combination with other options in the First recommended or alternative choices Adapted from GOLD 2013
  14. 14. Impact of Exacerbations in COPD Patients with Frequent Exacerbations Greater Airway InflammationFast Decline in lung function Higher Mortality Poorer Quality of Life
  15. 15. Inhaled CorticosteroidsInflammation plays central role in COPD & therapies aimed at halting or reversing inflammation are neededInhaled corticosteroids (ICS) decrease rate of exacerbation & may improve response to bronchodilators & decrease dyspnea in stable COPDNo studies show ICS reduce loss of lung functionStudies have not established a survival benefit when ICS is combined with long-acting B2 agonists
  16. 16. Roflumilast Overview First oral COPD specific anti-inflammatory therapy for patients with severe COPD who have symptoms of chronic cough and sputum, history of frequent exncerbations. and on maintenance bronchodilat0r therapy A potent and selective Inhibitor of the PDE4 enzyme, that targets the chronic inflammation underlying COPD Indicated in EU for maintenance treatment of severe COPD associated with chronic bronchitis in adult patients with a history of frequent exacerbations, as add-on to bronchodilator treatment Significantly reduced exacerbations and improved lung function when added to maintenance therapy with bronchodilators, in patients with severe COPD, symptoms of chronic bronchitis, a history of frequent exacerbations
  17. 17. Influenza Vaccination:Risk for Any ExacerbationEvaluation of results from randomized clinical trials indicates that inactivated influenza vaccine reduces exacerbations in COPD patientsThe magnitude of this benefit is similar to that seen in large observational studies, and was due to a reduction in exacerbations occurring three or more weeks after vaccination, and due to influenzaThere is a mild increase in transient local adverse effects with vaccination, but no evidence of an increase in early exacerbations.
  18. 18. Selecting an Appropriate Aerosol DeliveryDevice is Critical to Successfully Tx COPDThe number of different devices- each with different characteristics, requiring different inhalation techniques -can be confusing for the patient and the clinician.Consider the unique features of the Inhaler In relation to the ventilatory nuances imposed by the disease.Multiple devices are commonly used by patients with more severe disease, but can be confusing – leading to decreased adherence.
  19. 19. Pressurized Metered-doseInhalers (pMDIs)Most commonly used handheld aerosol delivery deviceNewer HFA-propellants provide an aerosol with lower forward jet velocity than the older CFC-propelled MDIsPotential issues: ▫ Hand-breath coordination ▫ Taking a slow rather than rapid inhalation ▫ whether to inhale from residual volume or functional capacity ▫ Length of breath-hold at end-inspiration ▫ Priming and shaking before use
  20. 20. Dry Powder Inhalers(DPIs)Breath-actuated- thus, eliminate many of the problems associated with coordinating pMDI actuation and inhalationPotential issues: ▫ Need for higher inspiratory flow rate vs. pMDI ▫ Resistance can vary 10"fold depending on design ▫ Inhaler preparation and failure to hold device correctly may contribute to high error rates in some patients
  21. 21. NebulizersAlternate to pMDIs and DPIs for providing aerosol therapy, provided that the drug is available in liquid formMost user-friendly of the inhaler devicesFrequently prescribed for patients with COPD ▫ Minimal coordination and effort is required during Inhalation compared to pMDIs and DPIs ▫ Aerosol is continuously produced ▫ Patient can sit comfortable, using tidal-volume breathing
  22. 22. Manage Stable COPDKey PointsRegular treatment with inhaled glucocorticosteroids is appropriate for symptomatic COPD patients with an FEV1 <50% predicted (Stage lll: Severe COPD and Stage IV: Very Severe COPD) and repeated exacerbations e.g. 3 in the last three years (Evidence A).This treatment has been shown to reduce the frequency of exacerbations and improve health status (Evidence A).
  23. 23. Manage Stable COPDKey PointsChronic treatment with systemic gluco- corticosteroids should be avoided because of an unfavorable benefit-to-risk ratio (Evidence A).All COPD-patients benefit from exercise training programs, improving with respect to both exercise tolerance and symptoms of dyspnea and fatigue (Evidence A).
  24. 24. Bronchodilators in Stable COPDBronchodilator medications are central to symptom management in COPDInhaled therapy is preferredThe choice between beta-2 agonist, anticholinergic, theophylline, or combination therapy depends on availability and individual response in terms of symptom relief and side effects
  25. 25. Life-Prolonging COPD TherapiesSupplemental oxygenSmoking cessationSurgery for selected patients: predominantly upper-lobe emphysema and low exercise capacity
  26. 26. NOTT StudyPatients received continuous O2 or nocturnal O2O2 dose adjusted for PaO2 of 60 - 80 mm Hg; increased by 1 L/min for exercise and sleep
  27. 27. MRC studyTreatment group received O2 at least 15h/d (including sleeping hours) at 2 L/min; higher if needed to achieve PaO2 >60 mmHg
  28. 28. NOTT StudyOne year mortality Two-year mortality ▫ ARR: 8.7% ▫ ARR: 18.4% ▫ RRR: 42.2% ▫ RRR: 45.1% ▫ NNT: 11.5 ▫ NNT: 5.4 MRC StudyFive-year mortality ▫ ARR: 21.5% ▫ RRR:32.2% ARR: Absolute Risk Reduction ▫ NNT: 4.65 RRR: Relative Risk Reduction NNT: Number Needed to Treat
  29. 29. Indications for LTOT Based on randomized controlled Based on Less Evidence clinical trials  Continuous oxygen use  Intermittent oxygen use ▫ Resting PaO2≤55 mm Hg ▫ Desaturation (Spo2≤ 88%) ▫ Resting PaO2 of 56-59 mm Hg with with activity any one of the following: ▫ Desaturation (Spo2≤ 88%)  Dependent Edema at night  P pulmonale on the electrocardiogram(P wave exceeding 3 mm in standard lead II, III or a VF)  Polycythemia( hematocrit,> 56%)Spo2 = oxygen saturation by pulse oximetry. Stoller, Chest 2010;138:179
  30. 30. Oxygen Source: CylindersNot practical as primary systemUsed as a backup for primary O2 system or for portability
  31. 31. Oxygen ConcentratorOxygen from air (≈ 90-95%)Most to 5 L/min; some to 10 L/minSimple; low maintenanceElectrically poweredBackup cylinder needed or portable concentratorLess patient phobia than other systemsConventional concentrators not portable
  32. 32. Transfilling Concentrators
  33. 33. Portable concentrators• Maximum O2 produced and the dosing of the O2 differ by concentrator.• If the patient increases the demand with a higher dose setting orrespiratory rate, either delivered dose. %O2, or both will decrease.
  34. 34. Liquid OxygenMore efficientBase unitPortable unit (filled from base)Higher flows availableRequires refillingBackup cylinder neededPatient phobia (thermal injury)
  35. 35. Oxygen Conserving DevicesPulse dose (battery powered): fixed volume per breath; use standard cannula ▫ O2 on every breath or on alternate breaths ▫ Vary dose by peak flow or durationDemand devices (pneumatically powered): deliver oxygen only during inhalation; use dual- lumen cannulaReservoir cannulaTranstracheal oxygen
  36. 36. Oxygen Conserving DevicesCylinders last longerFewer complications (drying, irritation, taste)Cylinder devices: fit on any cylinderLiquid devices: incorporated into deviceDifferent devices produce different oxygenation and different devices may respond differently to varying conditions (exercise, sleep).Prescription should be device specific
  37. 37. Reservoir Oxygen Cannula
  38. 38. Transtracheal OxygenOxygen delivered directly into the trachea through a surgically implanted catheterAdvantages: inconspicuous; lack of nasal. ear, and facial irritation; remains in place during sleep and exerciseComplications: subcutaneous emphysema, bronchospasm, and paroxysmal coughing during placement; late complications include dislodged catheters, stomal infections, mucous balls (may be fatal)
  39. 39. SummaryO2 therapy for the patient with COPD is life- savingO2 source can be cylinder, concentrator, or liquidPortable O2 is important (necessary!)O2 conserving devices extend the time patient can be away from fixed O2 sourceImportant for the clinician to appreciate differences between LTOT devices